104065-95-4 Usage
General Description
2-Isobutoxyaniline, also known as 4-methoxy-1-methyl-2-((methylamino)methyl)benzene, is an organic compound with the chemical formula C11H17NO. It is a colorless to pale yellow liquid that is used in the production of dyes and pigments, as well as in the synthesis of pharmaceuticals and agrochemicals. 2-Isobutoxyaniline is also utilized as a chemical intermediate in the manufacturing of various industrial products. It is considered to be a hazardous substance and should be handled with care due to its potential health risks and environmental impacts.
Check Digit Verification of cas no
The CAS Registry Mumber 104065-95-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,4,0,6 and 5 respectively; the second part has 2 digits, 9 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 104065-95:
(8*1)+(7*0)+(6*4)+(5*0)+(4*6)+(3*5)+(2*9)+(1*5)=94
94 % 10 = 4
So 104065-95-4 is a valid CAS Registry Number.
InChI:InChI=1/C10H15NO/c1-8(2)7-12-10-6-4-3-5-9(10)11/h3-6,8H,7,11H2,1-2H3
104065-95-4Relevant articles and documents
A structure—activity relationship study of bis-benzamides as inhibitors of androgen receptor—coactivator interaction
Lee, Tae-Kyung,Ravindranathan, Preethi,Sonavane, Rajni,Raj, Ganesh V.,Ahn, Jung-Mo
, (2019/08/07)
The interaction between androgen receptor (AR) and coactivator proteins plays a critical role in AR-mediated prostate cancer (PCa) cell growth, thus its inhibition is emerging as a promising strategy for PCa treatment. To develop potent inhibitors of the
THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS
-
Page/Page column 56, (2010/11/25)
The present invention relates to novel pharmaceutical compositions of general formula (I) comprising thienopyrimidine compounds. Moreover, the present invention relates to the use of the thienopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.
